OncoDaily GU (@OncoDailyGU)
@OncoDailyGU
226 正在关注 130 粉丝
ARTO long-term analysis
Adding SBRT to abiraterone acetate + prednisone + ADT may improve outcomes in selected patients with oligometastatic CRPC.
At 53-month median follow-up
• OS: not reached vs 50 mo
• HR 0.55; p=0.021
• bPFS: 44 vs 18 mo
• rPFS: 44 vs 17 mo
• 4-yr PC-specific survival: 86.6% vs 67.7%
No new safety concerns were reported.
@MicheleAquilano @alessiobruni @BarbaraJereczek @GabSimontacchi @PierluigiBonomo @ChadTangMD
#ProstateCancer# #GUOncology# #SBRT# #Oncology#
显示更多
